公开(公告)号：EP1259242A2

公开(公告)日：2002-11-27

申请号：EP01921298.4

申请日：2001-03-01

Applicant: Novartis AG ,  The University of Melbourne ,  Southern Health ,  Atkins, Robert ,  Chadban, Steven James ,  Cooper, Mark Emmanuel ,  Gilbert, Richard Ernest ,  Hill, Prudence Ann ,  Kelly, Darren James ,  Nikolic-Paterson, David John

Inventor： ATKINS, Robert, Charles ,  CHADBAN, Steven, James ,  COOPER, Mark, Emmanuel ,  GILBERT, Richard, Ernest ,  HILL, Prudence, Ann ,  KELLY, Darren, James ,  NIKOLIC-PATERSON, David, John

IPC: A61K31/505 ,  A61K31/506 ,  A61K31/00 ,  A61P13/12

CPC classification number: A61K31/5377 ,  A61K31/00 ,  A61K31/505 ,  A61K31/506

Abstract: The present invention relates to the use of PDGF receptor tyrosine kinase inhibitors, especially of N-phenyl-2-pyrimidine-amine derivatives of formula (I), in which the symbols and substituents have the meaning as defined herein in free form or in pharmaceutically acceptable salt form, in the manufacture of a pharmaceutical composition for the treatment of diabetic nephropathy; to a method of treatment of warm-blooded animals, including humans, suffering from diabetic nephropathy; and to the use of a PDGF receptor tyrosine kinase inhibitor of the formula (I), wherein R1, is pyridyl bonded at a carbon atom, R2, R3, R5, R6 and R8 are each hydrogen, R4 is lower alkyl, R7 a radical of formula (II):-N(R9)-C(=X)-(Y)n-R10, wherein R9 is hydrogen, X is oxo, n is 0 and R10 is 4-methyl-piperazinyl-methyl, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating glomerulonephritis, chronic pyelonephritis or IgA nephropathy.

公开(公告)号：EP1259242B1

公开(公告)日：2007-08-15

申请号：EP01921298.4

申请日：2001-03-01

Applicant: Novartis AG ,  The University of Melbourne ,  Southern Health ,  Atkins, Robert ,  Chadban, Steven James ,  Cooper, Mark Emmanuel ,  Gilbert, Richard Ernest ,  Hill, Prudence Ann ,  Kelly, Darren James ,  Nikolic-Paterson, David John ,  Novartis Pharma GmbH

Inventor： ATKINS, Robert, Charles ,  CHADBAN, Steven, James ,  COOPER, Mark, Emmanuel ,  GILBERT, Richard, Ernest ,  HILL, Prudence, Ann ,  KELLY, Darren, James ,  NIKOLIC-PATERSON, David, John

IPC: A61K31/505 ,  A61K31/506 ,  A61K31/00 ,  A61P13/12

CPC classification number: A61K31/5377 ,  A61K31/00 ,  A61K31/505 ,  A61K31/506

Abstract: The present invention relates to the use of PDGF receptor tyrosine kinase inhibitors, especially of N-phenyl-2-pyrimidine-amine derivatives of formula (I), in which the symbols and substituents have the meaning as defined herein in free form or in pharmaceutically acceptable salt form, in the manufacture of a pharmaceutical composition for the treatment of diabetic nephropathy; to a method of treatment of warm-blooded animals, including humans, suffering from diabetic nephropathy; and to the use of a PDGF receptor tyrosine kinase inhibitor of the formula (I), wherein R1, is pyridyl bonded at a carbon atom, R2, R3, R5, R6 and R8 are each hydrogen, R4 is lower alkyl, R7 a radical of formula (II):-N(R9)-C(=X)-(Y)n-R10, wherein R9 is hydrogen, X is oxo, n is 0 and R10 is 4-methyl-piperazinyl-methyl, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating glomerulonephritis, chronic pyelonephritis or IgA nephropathy.

公开(公告)号：GB201415805D0

公开(公告)日：2014-10-22

申请号：GB201415805

申请日：2014-09-08

Applicant: ATKINS ROBERT M

公开(公告)号：WO0164200A3

公开(公告)日：2002-01-17

申请号：PCT/EP0102340

申请日：2001-03-01

Applicant: NOVARTIS AG ,  UNIV MELBOURNE ,  SOUTHERN HEALTH ,  ATKINS ROBERT CHARLES ,  CHADBAN STEVEN JAMES ,  COOPER MARK EMMANUEL ,  GILBERT RICHARD ERNEST ,  HILL PRUDENCE ANN ,  KELLY DARREN JAMES ,  NIKOLIC PATERSON DAVID JOHN

Inventor： ATKINS ROBERT CHARLES ,  CHADBAN STEVEN JAMES ,  COOPER MARK EMMANUEL ,  GILBERT RICHARD ERNEST ,  HILL PRUDENCE ANN ,  KELLY DARREN JAMES ,  NIKOLIC-PATERSON DAVID JOHN

IPC: C07D401/14 ,  A61K31/00 ,  A61K31/505 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/00 ,  A61P13/12 ,  A61P43/00

CPC classification number: A61K31/5377 ,  A61K31/00 ,  A61K31/505 ,  A61K31/506

Abstract: The present invention relates to the use of PDGF receptor tyrosine kinase inhibitors, especially of N-phenyl-2-pyrimidine-amine derivatives of formula (I), in which the symbols and substituents have the meaning as defined herein in free form or in pharmaceutically acceptable salt form, in the manufacture of a pharmaceutical composition for the treatment of diabetic nephropathy; to a method of treatment of warm-blooded animals, including humans, suffering from diabetic nephropathy; and to the use of a PDGF receptor tyrosine kinase inhibitor of the formula (I), wherein R1, is pyridyl bonded at a carbon atom, R2, R3, R5, R6 and R8 are each hydrogen, R4 is lower alkyl, R7 a radical of formula (II):-N(R9)-C(=X)-(Y)n-R10, wherein R9 is hydrogen, X is oxo, n is 0 and R10 is 4-methyl-piperazinyl-methyl, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating glomerulonephritis, chronic pyelonephritis or IgA nephropathy.

Abstract translation: 本发明涉及PDGF受体酪氨酸激酶抑制剂，特别是式（I）的N-苯基-2-嘧啶 - 胺衍生物的用途，其中符号和取代基具有如本文定义的含义为游离形式或药学上 在制备用于治疗糖尿病性肾病的药物组合物中的可接受的盐形式; 涉及一种治疗患有糖尿病肾病的温血动物（包括人）的方法; 以及使用式（I）的PDGF受体酪氨酸激酶抑制剂，其中R1是在碳原子上键合的吡啶基，R2，R3，R5，R6和R8各自为氢，R4为低级烷基，R7为自由基 的式（II）：-N（R 9）-C（= X） - （Y）n -R 10，其中R 9是氢，X是氧代，n是0，R 10是4-甲基 - 哌嗪基 - 甲基，或 其药学上可接受的盐用于制备用于治疗肾小球性肾炎，慢性肾盂肾炎或IgA肾病的药物。

公开(公告)号：WO1996001186A1

公开(公告)日：1996-01-18

申请号：PCT/NZ1995000056

申请日：1995-06-20

Applicant: ATKINS, Robert ,  JOHNSON, Colin, Francis ,  TROTTER, Peter, Royce

IPC: B41J31/14

CPC classification number: B29C66/1122 ,  B29C65/222 ,  B29C65/226 ,  B29C65/228 ,  B29C65/229 ,  B29C66/0044 ,  B29C66/032 ,  B29C66/43 ,  B29C66/4324 ,  B29C66/71 ,  B29C66/8122 ,  B29C66/81821 ,  B29C66/81871 ,  B29C66/91231 ,  B29C66/91421 ,  B29C66/91653 ,  B29C66/91655 ,  B29C2793/009 ,  B29L2031/7674 ,  B41J31/14 ,  B29K2827/18 ,  B29K2077/00

Abstract: Portable apparatus (700) for replacement of a used ribbon with an inked thermoplastic (such as nylon) ribbon within an existing ribbon cartridge for an impact printer comprises: dispensing means (730) for one or more widths of ribbon, metering means (721) to measure the length dispensed, a motor drive (704) to move the ribbon through the cartridge, a heat-sealing device (720) for joining thermoplastic ribbons end-to-end, and trimming means to remove surplus material at the join. The heat-sealing device (720) is electrically heated under control, and the gap between its heatable jaws is controlled in order to limit any tendency to thicken. A method for use of the portable apparatus (700) includes cutting the old ribbon at an exposed position, joining new ribbon to the old, pulling the new ribbon through the cartridge, and when it emerges, joining new ribbon to new ribbon so that an endless loop is formed.

Abstract translation: 用于冲击打印机的现有色带墨盒内用墨水热塑性塑料（如尼龙）色带替换用过的色带的便携式设备（700）包括：用于一个或多个色带宽度的分配装置（730），计量装置（721） 以测量分配的长度，用于将带移动通过盒的电动机驱动器（704），用于将热塑性带端对端连接的热封装置（720）和用于在连接处去除剩余材料的修整装置。 热封装置（720）在控制下被电加热，并且控制其可加热夹爪之间的间隙以限制任何增厚的倾向。 便携式设备（700）的使用方法包括：在暴露位置切割旧色带，将新色带连接到旧色带，将新色带通过盒带拉出，并且当其出现时，将新色带连接到新色带，使得 形成无限循环。

公开(公告)号：ES2291306T3

公开(公告)日：2008-03-01

申请号：ES01921298

申请日：2001-03-01

Applicant: NOVARTIS AG ,  UNIV MELBOURNE ,  SOUTHERN HEALTH ,  ATKINS ROBERT ,  CHADBAN STEVEN JAMES ,  COOPER MARK EMMANUEL

Inventor： ATKINS ROBERT CHARLES ,  CHADBAN STEVEN JAMES ,  COOPER MARK EMMANUEL ,  GILBERT RICHARD ERNEST ,  HILL PRUDENCE ANN ,  KELLY DARREN JAMES

IPC: A61K31/505 ,  C07D401/14 ,  A61K31/00 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/00 ,  A61P13/12 ,  A61P43/00

Abstract: Uso de un inhibidor tirosina quinasa del receptor PDGF de la fórmula I, en donde R1 es 4-pirazinil; 1-metil-1H-pirrolil; amino- o amino-alquil C1-7- fenil sustituido, en donde el grupo amino en cada caso es libre, alquilado o acilado; el 1 H-indolil o el 1H-imidazolil unido a un anillo de cinco miembros de átomos de carbono; o no sustituido o alquil C1-7- piridil sustituido unido a un anillo de un átomo de carbono y no sustituido o sustituido en el átomo de nitrógeno por un oxígeno; R2 y R3 son cada uno independientemente del otro hidrógeno o alquil C1-7; uno o dos de los radicales R4, R5, R6, R7 y R8 son cada uno nitro, alcoxi C1-7 fluoro-sustituido o un radical de la fórmula II -N(R9)-C(=X)-(Y)nR10 (II), en donde R9 es hidrógeno o alquil C1-7, X es oxo, tio, imino, N-alquil C1-7-imino, hidroximino u O-alquil C1-7-hidroximino, Y es oxígeno o el grupo NH, n es 0 o 1 y R10 es un radical alifático que tiene al menos 5 átomos de carbono, o un radical aromático, aromático-alifático,cicloalifático, cicloalifático-alifático, heterocíclico o heterocíclico-alifático, y los radicales restantes R4, R5, R6, R7 y R8 son cada uno independientemente de los otros hidrógeno, alquil C1-7 que es no sustituido o sustituido por un amino libre o alquilado, piperazinil, piperidinil, pirrolidinil o por un morfolinil, o alcanoil C1-7, trifluorometil, hidroxi libre, eterificado o esterificado, amino libre, alquilado o acilado o carboxi libre o esterificado, o una sal de dichos compuestos que tenga al menos un grupo formador de sal, para la elaboración de un medicamento para el tratamiento de la nefropatía diabética.

公开(公告)号：CA2401812A1

公开(公告)日：2001-09-07

申请号：CA2401812

申请日：2001-03-01

Applicant: NOVARTIS AG ,  UNIV MELBOURNE ,  GILBERT RICHARD ERNEST ,  SOUTHERN HEALTH ,  HILL PRUDENCE ANN ,  ATKINS ROBERT CHARLES ,  NIKOLIC-PATERSON DAVID JOHN ,  KELLY DARREN JAMES ,  CHADBAN STEVEN JAMES ,  COOPER MARK EMMANUEL

Inventor： GILBERT RICHARD ERNEST ,  HILL PRUDENCE ANN ,  ATKINS ROBERT CHARLES ,  NIKOLIC-PATERSON DAVID JOHN ,  KELLY DARREN JAMES ,  CHADBAN STEVEN JAMES ,  COOPER MARK EMMANUEL

IPC: C07D401/14 ,  A61K31/00 ,  A61K31/505 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/00 ,  A61P13/12 ,  A61P43/00

Abstract: The present invention relates to the use of PDGF receptor tyrosine kinase inhibitors, especially of N-phenyl-2-pyrimidine-amine derivatives of formula (I), in which the symbols and substituents have the meaning as defined herei n in free form or in pharmaceutically acceptable salt form, in the manufacture of a pharmaceutical composition for the treatment of diabetic nephropathy; t o a method of treatment of warm-blooded animals, including humans, suffering from diabetic nephropathy; and to the use of a PDGF receptor tyrosine kinase inhibitor of the formula (I), wherein R1, is pyridyl bonded at a carbon atom , R2, R3, R5, R6 and R8 are each hydrogen, R4 is lower alkyl, R7 a radical of formula (II):-N(R9)-C(=X)-(Y)n-R10, wherein R9 is hydrogen, X is oxo, n is 0 and R10 is 4-methyl-piperazinyl-methyl, or a pharmaceutically acceptable sal t thereof for the manufacture of a medicament for treating glomerulonephritis, chronic pyelonephritis or IgA nephropathy.

公开(公告)号：AU2005244525A1

公开(公告)日：2006-01-12

申请号：AU2005244525

申请日：2005-12-14

Applicant: ATKINS ROBERT CHARLES ,  CHADBAN STEVEN JAMES ,  COOPER MARK EMMANUEL ,  GILBERT RICHARD ERNEST ,  HILL PRUDENCE ANN ,  KELLY DARREN JAMES ,  NIKOLIC PATERSON DAVID JOHN ,  SOUTHERN HEALTH ,  UNIV MELBOURNE

Inventor： HILL PRUDENCE ANN ,  NIKOLIC-PATERSON DAVID JOHN ,  CHADBAN STEVEN JAMES ,  COOPER MARK EMMANUEL ,  GILBERT RICHARD ERNEST ,  KELLY DARREN JAMES ,  ATKINS ROBERT CHARLES

IPC: A61K31/00 ,  A61K31/505 ,  A61K31/506 ,  A61P13/12

公开(公告)号：AU4832401A

公开(公告)日：2001-09-12

申请号：AU4832401

申请日：2001-03-01

Applicant: NOVARTIS AG ,  CHADBAN STEVEN JAMES ,  COOPER MARK EMMANUEL ,  GILBERT RICHARD ERNEST ,  HILL PRUDENCE ANN ,  KELLY DARREN JAMES ,  PATERSON DAVID JOHN NIKOLIC ,  UNIV MELBOURNE ,  SOUTHERN HEALTH ,  ATKINS ROBERT CHARLES

Inventor： ATKINS ROBERT CHARLES ,  CHADBAN STEVEN JAMES ,  COOPER MARK EMMANUEL ,  GILBERT RICHARD ERNEST ,  HILL PRUDENCE ANN ,  KELLY DARREN JAMES ,  NIKOLIC-PATERSON DAVID JOHN

IPC: C07D401/14 ,  A61K31/00 ,  A61K31/505 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/00 ,  A61P13/12 ,  A61P43/00

Abstract: The present invention relates to the use of PDGF receptor tyrosine kinase inhibitors, especially of N-phenyl-2-pyrim-idine-amine derivatives of formula (I), in which the symbols and substituents have the meaning as defined herein in free form or in pharmaceutically acceptable salt form, in the manufacture of a pharmaceutical composition for the treatment of diabetic nephropathy; to a method of treatment of warm-blooded animals, including humans, suffering from diabetic nephropathy; and to the use of a PDGF receptor tyrosine kinase inhibitor of the formula (I), wherein R 1 is pyridyl bonded at a carbon atom, R 2 , R 3 , R 5 , R 6 and R 8 are each hydrogen, R 4 is lower alkyl, R 7 a radical of formula (II): -N(R 9 )-C(-X)-(Y) n -R 10 , wherein R 9 hydrogen, X is oxo, n is 0 and R 10 is 4-methyl-piperazinyl-methyl, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating glomerulonephritis, chronic pyelonephritis or IgA nephropathy.

公开(公告)号：AU6058780A

公开(公告)日：1981-02-03

申请号：AU6058780

申请日：1980-07-04

Applicant: ATKINS ROBERT CHARLES ,  TRAVENOL LABORATORIES PTY LTD ,  WILLIAMS ROBERT PAUL

Inventor： ATKINS R C ,  WILLIAMS R P

IPC: A61M5/00 ,  A61M5/31 ,  F16L21/00 ,  F16L35/00 ,  F16L37/00 ,  F16L47/00